This page shows the latest SNG001 news and features for those working in and with pharma, biotech and healthcare.
SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. ... Further, 58% of the patients in the SNG001 group had recovered on day 28,
Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... In exacerbating patients who already required treatment with
The double-blind, placebo-controlled phase 1 trial of SNG001 recruited 101 hospitalised COVID-19 patients from nine hospital sites across the UK. ... While three patients died after being randomised to receive the placebo, no deaths were observed among
SNG001 (inhaled formulation of interferon-beta-1a), as concerns grow in the UK that COVID-19 cases could soar in the comings weeks. ... SNG001 delivers a formulation of INF-beta-1a to the lungs directly via nebulisation, and is suitable for inhaled
The novel formulation - called SNG001 - is designed to prevent the sometimes severe exacerbations suffered by asthma patients when they develop respiratory viral infections such as colds. ... The big pharma company will also meet all future development
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...